Catalyst Pharmaceuticals, Inc.: Firdapse approved in Nov 2018 for Lambert-Eaton Myasthenic Syndrome (LEMS) - 2 positive Ph 3s complete, potential launch early '19. Addl ongoing trials in congenital myasthenic syndromes (CMS), MuSK myasthenia gravis & Spinal Muscular Atrophy Type 3.
Healthcare/Drug Manufacturers
Based in...
Clinical Stage
Phase III, Registration Stage
Disease Space
Central Nervous System, Rare Disease
Specialty Pharmaceutical
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Small Molecule
355 Alhambra Circle
Suite 1250
Coral Gables, FL 33134
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Clients at Jefferies

New York, NY, United States, June 4 – June 7, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.